Floatz logo

Fenretinide

Recurrent Marginal Zone Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Recurrent Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
Monomethyl Fumarate
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 50 →

Same molecule, other indications

Fenretinide is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
58 / 100
View asset →
cancerDormant
B
Indicative ·
56 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →